JP2024119842A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024119842A5 JP2024119842A5 JP2024083232A JP2024083232A JP2024119842A5 JP 2024119842 A5 JP2024119842 A5 JP 2024119842A5 JP 2024083232 A JP2024083232 A JP 2024083232A JP 2024083232 A JP2024083232 A JP 2024083232A JP 2024119842 A5 JP2024119842 A5 JP 2024119842A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- heart failure
- patient
- hospitalization
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010019280 Heart failures Diseases 0.000 claims 54
- 239000008194 pharmaceutical composition Substances 0.000 claims 36
- 208000024891 symptom Diseases 0.000 claims 13
- 230000002526 effect on cardiovascular system Effects 0.000 claims 11
- 239000002131 composite material Substances 0.000 claims 8
- 230000000977 initiatory effect Effects 0.000 claims 7
- 206010000891 acute myocardial infarction Diseases 0.000 claims 6
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 claims 5
- 229960003834 dapagliflozin Drugs 0.000 claims 5
- 102000017011 Glycated Hemoglobin A Human genes 0.000 claims 3
- 238000003745 diagnosis Methods 0.000 claims 3
- 239000002934 diuretic Substances 0.000 claims 3
- 229940030606 diuretics Drugs 0.000 claims 3
- 108091005995 glycated hemoglobin Proteins 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- 206010007556 Cardiac failure acute Diseases 0.000 claims 2
- 102400001263 NT-proBNP Human genes 0.000 claims 2
- 208000006117 ST-elevation myocardial infarction Diseases 0.000 claims 2
- 208000038002 heart failure with reduced ejection fraction Diseases 0.000 claims 2
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 238000002642 intravenous therapy Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000002861 ventricular Effects 0.000 claims 1
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962893849P | 2019-08-30 | 2019-08-30 | |
| US62/893,849 | 2019-08-30 | ||
| US201962930673P | 2019-11-05 | 2019-11-05 | |
| US62/930,673 | 2019-11-05 | ||
| US201962946625P | 2019-12-11 | 2019-12-11 | |
| US62/946,625 | 2019-12-11 | ||
| US202062960756P | 2020-01-14 | 2020-01-14 | |
| US62/960,756 | 2020-01-14 | ||
| US202062969181P | 2020-02-03 | 2020-02-03 | |
| US62/969,181 | 2020-02-03 | ||
| US202062985407P | 2020-03-05 | 2020-03-05 | |
| US62/985,407 | 2020-03-05 | ||
| JP2020524303A JP7756487B2 (ja) | 2019-08-30 | 2020-03-09 | ダパグリフロジンを用いて、駆出率が低下した心不全を治療する方法 |
| PCT/EP2020/056211 WO2021037400A1 (en) | 2019-08-30 | 2020-03-09 | Methods of treating heart failure with reduced ejection fraction with dapagliflozin |
| JP2022194700A JP7494277B2 (ja) | 2019-08-30 | 2022-12-06 | ダパグリフロジンを用いて、駆出率が低下した心不全を治療する方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022194700A Division JP7494277B2 (ja) | 2019-08-30 | 2022-12-06 | ダパグリフロジンを用いて、駆出率が低下した心不全を治療する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024119842A JP2024119842A (ja) | 2024-09-03 |
| JP2024119842A5 true JP2024119842A5 (https=) | 2025-01-29 |
Family
ID=69784449
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020524303A Active JP7756487B2 (ja) | 2019-08-30 | 2020-03-09 | ダパグリフロジンを用いて、駆出率が低下した心不全を治療する方法 |
| JP2022194700A Active JP7494277B2 (ja) | 2019-08-30 | 2022-12-06 | ダパグリフロジンを用いて、駆出率が低下した心不全を治療する方法 |
| JP2024083232A Pending JP2024119842A (ja) | 2019-08-30 | 2024-05-22 | ダパグリフロジンを用いて、駆出率が低下した心不全を治療する方法 |
| JP2025062458A Pending JP2025108488A (ja) | 2019-08-30 | 2025-04-04 | ダパグリフロジンを用いて、駆出率が低下した心不全を治療する方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020524303A Active JP7756487B2 (ja) | 2019-08-30 | 2020-03-09 | ダパグリフロジンを用いて、駆出率が低下した心不全を治療する方法 |
| JP2022194700A Active JP7494277B2 (ja) | 2019-08-30 | 2022-12-06 | ダパグリフロジンを用いて、駆出率が低下した心不全を治療する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025062458A Pending JP2025108488A (ja) | 2019-08-30 | 2025-04-04 | ダパグリフロジンを用いて、駆出率が低下した心不全を治療する方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10973836B2 (https=) |
| EP (1) | EP4021507A1 (https=) |
| JP (4) | JP7756487B2 (https=) |
| KR (3) | KR102359799B1 (https=) |
| CN (1) | CN112752582A (https=) |
| AU (4) | AU2020202887B2 (https=) |
| BR (1) | BR112020008705A2 (https=) |
| CA (1) | CA3079175A1 (https=) |
| CL (1) | CL2020001335A1 (https=) |
| CR (1) | CR20200224A (https=) |
| IL (1) | IL274020A (https=) |
| JO (1) | JOP20200098A1 (https=) |
| MX (2) | MX2020005388A (https=) |
| PE (1) | PE20211267A1 (https=) |
| PH (1) | PH12020551141A1 (https=) |
| SG (1) | SG11202003971RA (https=) |
| TW (3) | TWI786398B (https=) |
| WO (1) | WO2021037400A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021000139A2 (pt) | 2018-07-19 | 2021-04-06 | Astrazeneca Ab | Métodos de tratamento da hfpef empregando dapagliflozina e composições compreendendo a mesma |
| WO2021037400A1 (en) | 2019-08-30 | 2021-03-04 | Astrazeneca Ab | Methods of treating heart failure with reduced ejection fraction with dapagliflozin |
| EP4138826A1 (en) * | 2020-04-22 | 2023-03-01 | Bayer Aktiengesellschaft | Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases |
| US20240100013A1 (en) * | 2021-01-04 | 2024-03-28 | Lexicon Pharmaceuticals, Inc. | Sotagliflozin for improving left atrial function |
| US20250108065A1 (en) | 2022-01-26 | 2025-04-03 | Astrazeneca Ab | Methods of treating prediabetes or reducing the risk of developing type 2 diabetes with dapagliflozin |
| JP7396579B2 (ja) * | 2022-01-31 | 2023-12-12 | 壽製薬株式会社 | 左室駆出率が保たれた心不全に対する医薬組成物 |
| WO2023175573A1 (en) * | 2022-03-17 | 2023-09-21 | Zydus Lifesciences Limited | Pharmaceutical compositions comprising a β-blocker and an sglt2 inhibitor |
| US20250205317A1 (en) * | 2022-03-28 | 2025-06-26 | University Of Maryland, Baltimore | Methods and compositions for the treatment of stroke |
| CR20250112A (es) * | 2022-09-01 | 2025-08-18 | Aztrazeneca Ab | Combinación de ihnibidores de sglt2 y moduladores del receptor mineralcorticoide para usar en el tratamiento de enfermedades cardiorrenales |
| EP4640213A1 (en) * | 2022-12-20 | 2025-10-29 | THPharm Corp. | Oral pharmaceutical preparation comprising sodium-glucose cotransporter-2 inhibitor and angiotensin ii receptor blocker |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| WO2007093610A1 (en) | 2006-02-15 | 2007-08-23 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture |
| TW200904454A (en) * | 2007-03-22 | 2009-02-01 | Bristol Myers Squibb Co | Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof |
| AR065809A1 (es) * | 2007-03-22 | 2009-07-01 | Bristol Myers Squibb Co | Formulaciones farmaceuticas que contienen un inhibidor sglt2 |
| JP2011506363A (ja) | 2007-12-11 | 2011-03-03 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | 心不全の処置および／または予防用のオキサゾリジノン類 |
| CA2812016A1 (en) | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| MX367404B (es) | 2014-06-30 | 2019-08-20 | Astrazeneca Ab | Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides. |
| JP2017528499A (ja) * | 2014-09-25 | 2017-09-28 | アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ | 肝臓の疾患を治療するためのオメガ３脂肪酸とｓｇｌｔ−２阻害薬との併用剤 |
| AU2017233889B2 (en) | 2016-03-16 | 2022-07-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising empagliflozin and uses thereof |
| EP3508222A4 (en) * | 2016-08-30 | 2020-04-29 | Niigata University | MEDICINES FOR REMOVING AGED CELLS |
| WO2018142422A1 (en) | 2017-02-02 | 2018-08-09 | Indoco Remedies Limited | Process for the preparation of dapagliflozin |
| KR101943382B1 (ko) | 2017-09-19 | 2019-01-29 | 오토텔릭바이오 주식회사 | Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물 |
| BR112021000139A2 (pt) | 2018-07-19 | 2021-04-06 | Astrazeneca Ab | Métodos de tratamento da hfpef empregando dapagliflozina e composições compreendendo a mesma |
| WO2021037400A1 (en) | 2019-08-30 | 2021-03-04 | Astrazeneca Ab | Methods of treating heart failure with reduced ejection fraction with dapagliflozin |
| TW202220672A (zh) * | 2020-07-27 | 2022-06-01 | 瑞典商阿斯特捷利康公司 | 用達格列淨治療慢性腎臟病之方法 |
-
2020
- 2020-03-09 WO PCT/EP2020/056211 patent/WO2021037400A1/en not_active Ceased
- 2020-03-09 JO JOP/2020/0098A patent/JOP20200098A1/ar unknown
- 2020-03-09 CA CA3079175A patent/CA3079175A1/en active Pending
- 2020-03-09 PE PE2020000563A patent/PE20211267A1/es unknown
- 2020-03-09 BR BR112020008705A patent/BR112020008705A2/pt not_active Application Discontinuation
- 2020-03-09 SG SG11202003971RA patent/SG11202003971RA/en unknown
- 2020-03-09 US US16/812,745 patent/US10973836B2/en active Active
- 2020-03-09 AU AU2020202887A patent/AU2020202887B2/en active Active
- 2020-03-09 MX MX2020005388A patent/MX2020005388A/es unknown
- 2020-03-09 KR KR1020207012588A patent/KR102359799B1/ko active Active
- 2020-03-09 JP JP2020524303A patent/JP7756487B2/ja active Active
- 2020-03-09 KR KR1020217014553A patent/KR20220044234A/ko not_active Ceased
- 2020-03-09 EP EP20710490.2A patent/EP4021507A1/en active Pending
- 2020-03-09 CR CR20200224A patent/CR20200224A/es unknown
- 2020-03-09 KR KR1020247038499A patent/KR20240166611A/ko active Pending
- 2020-03-09 CN CN202080000531.4A patent/CN112752582A/zh active Pending
- 2020-04-19 IL IL274020A patent/IL274020A/en unknown
- 2020-04-30 TW TW109114687A patent/TWI786398B/zh active
- 2020-04-30 TW TW111145734A patent/TWI859649B/zh active
- 2020-04-30 TW TW113137483A patent/TW202504616A/zh unknown
- 2020-05-01 PH PH12020551141A patent/PH12020551141A1/en unknown
- 2020-05-20 CL CL2020001335A patent/CL2020001335A1/es unknown
- 2020-07-13 MX MX2022008018A patent/MX2022008018A/es unknown
-
2021
- 2021-02-25 US US17/184,746 patent/US11903955B2/en active Active
- 2021-08-10 AU AU2021215150A patent/AU2021215150B2/en active Active
-
2022
- 2022-12-06 JP JP2022194700A patent/JP7494277B2/ja active Active
-
2023
- 2023-07-31 AU AU2023210548A patent/AU2023210548B2/en active Active
-
2024
- 2024-01-11 US US18/410,094 patent/US20240216404A1/en active Pending
- 2024-05-22 JP JP2024083232A patent/JP2024119842A/ja active Pending
-
2025
- 2025-04-04 JP JP2025062458A patent/JP2025108488A/ja active Pending
- 2025-06-17 AU AU2025204486A patent/AU2025204486A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024119842A5 (https=) | ||
| Helgeland | Treatment of mild hypertension: a five year controlled drug trial: the Oslo study | |
| Hunt et al. | 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation | |
| Chatterjee et al. | Oral hydralazine therapy for chronic refractory heart failure. | |
| Mehta et al. | Comparative hemodynamic effects of intravenous nitroprusside and oral prazosin in refractory heart failure | |
| Catalano et al. | Hypocalcemia: a sometimes overlooked cause of heart failure in the elderly | |
| Çap et al. | The effect of favipiravir on QTc interval in patients hospitalized with coronavirus disease 2019 | |
| Maak et al. | Should acute treatment with inhaled beta agonists be withheld from patients with dyspnea who may have heart failure? | |
| Caplan et al. | Almitrine infusion in severe acute respiratory syndrome coronavirus 2-induced acute respiratory distress syndrome: a single-center observational study | |
| Dalekos et al. | Lessons from pathophysiology: Use of individualized combination treatments with immune interventional agents to tackle severe respiratory failure in patients with COVID-19 | |
| Kupferschmid et al. | Amiodarone-induced complications after cardiac operation for obstructive hypertrophic cardiomyopathy | |
| JP2021530517A5 (https=) | ||
| Nilsson et al. | Prospective study of autonomic nerve function in type 1 and type 2 diabetic patients: 24 hour heart rate variation and plasma motilin levels disturbed in parasympathetic neuropathy | |
| Yassari et al. | Can L-carnitine supplementation improve cardiopulmonary function? A randomized controlled clinical trial in hemodialysis patients | |
| Ishizaki et al. | OP-1206, a prostaglandin E1 derivative: effects of oral administration to patients with chronic lung disease | |
| Sadeghi et al. | Nicardipine associated risk of short-term mortality in critically ill patients with ischemic stroke | |
| JP2020523408A (ja) | ２型糖尿病の患者における心血管イベントの低減又は予防方法 | |
| Kiernan et al. | Epoprostenol sodium (prostacyclin) infusion in acute myocardial infarction. | |
| Kai et al. | More attention should be paid to abnormalities of circadian blood pressure rhythm in heart failure patients | |
| Ning et al. | The influence of metoprolol in patients with sepsis-induced cardiomyopathy: a retrospective study | |
| Wenna et al. | The influence of metoprolol in patients with sepsis-induced cardiomyopathy | |
| Zhang | Treatment of Dilated Cardiomyopathy with Qilan Qiangxin Capsule Combined with Sakubatra and Valsartan: A Case Report | |
| Kabanga et al. | Junctional Bradycardia with Cardiorenal Syndrome | |
| Jin et al. | Effects of Sacubitril Valsartan Combined With Vericiguat on NT‐proBNP and CK‐MB Levels in Patients With Chronic Heart Failure | |
| TH2101000042A (th) | วิธีการบำบัด HFpEF ที่ใช้ดาพากลิโฟลซินและองค์ประกอบที่ประกอบรวมด้วยสิ่งดังกล่าว |